In April 2026, a patient in New Zealand reported being prescribed Wegovy (semaglutide) by an online general practitioner without undergoing a baseline weight assessment, raising concerns about telehealth prescribing practices for obesity medications and their potential impact on Novo Nordisk’s (NYSE: NVO) market dynamics and regulatory scrutiny. The incident highlights gaps in virtual care protocols that could trigger stricter oversight, affecting investor confidence in the weight-loss drug sector amid slowing growth forecasts and intensifying competition from Eli Lilly’s (NYSE: LLY) Zepbound and pipeline candidates.
The Bottom Line
- Novo Nordisk’s obesity care segment faces potential regulatory headwinds as telehealth prescribing loopholes draw scrutiny from the FDA and EMA.
- Wegovy’s U.S. Sales growth decelerated to 12% YoY in Q1 2026, down from 45% in Q1 2025, amid supply constraints and competitor gains.
- Eli Lilly’s Zepbound captured 38% of new GLP-1 prescriptions in March 2026, up from 29% in December 2025, pressuring Novo Nordisk’s market share.
Telehealth Prescribing Gaps Expose Regulatory Vulnerabilities in Obesity Drug Market
The 1News report details a case where a New Zealand patient received a Wegovy prescription via an online consultation without weight measurement, contradicting Novo Nordisk’s own prescribing guidelines and international clinical standards for semaglutide apply. Although the patient reported positive outcomes, the absence of baseline metrics raises safety concerns, particularly regarding off-label use and dosing accuracy in virtual settings. This incident follows similar reports in Australia and Canada, prompting telehealth platforms like Teladoc (NYSE: TDOC) and Amwell (NYSE: AMWL) to review prescribing algorithms for GLP-1 agonists.
Regulatory bodies are taking note. In March 2026, the FDA issued a draft guidance reinforcing that telehealth prescriptions for obesity medications must include verifiable baseline and follow-up weight metrics, citing a 22% increase in adverse event reports linked to remote prescribing since 2023. The European Medicines Agency (EMA) launched a parallel review in April 2026, focusing on cross-border telehealth prescriptions within the EU. These developments could increase compliance costs for digital health providers and slow patient access to obesity therapies.
Novo Nordisk’s Growth Slows Amid Intensifying Competition and Supply Challenges
Despite reporting $21.3 billion in global sales for 2025, Novo Nordisk’s obesity care segment showed signs of maturation in early 2026. Wegovy U.S. Sales reached $4.1 billion in Q1 2026, representing a 12% YoY increase—down sharply from 45% growth in the prior-year quarter—according to the company’s April 2026 earnings release. Gross margin for the obesity care division fell to 78.3% in Q1 2026 from 82.1% in Q1 2025, reflecting higher manufacturing costs and rebate pressures under U.S. Medicare Part D negotiations.
Supply constraints persist, with Novo Nordisk acknowledging in its Q1 2026 call that manufacturing capacity for semaglutide active pharmaceutical ingredient (API) remains at 92% utilization, limiting its ability to fully meet demand. The company has committed $6.5 billion to expand production facilities in Denmark and the U.S. Through 2028, but analysts at JPMorgan note that full-scale output will not alleviate shortages until late 2027.
Eli Lilly Gains Ground as Zepbound Accelerates Market Share Capture
While Novo Nordisk navigates operational headwinds, Eli Lilly has accelerated its challenge in the obesity market. Zepbound (tirzepatide) U.S. Sales hit $2.8 billion in Q1 2026, growing 89% YoY, and captured 38% of new GLP-1 prescriptions in March 2026, according to IQVIA data cited in Lilly’s April 2026 earnings transcript. Lilly’s CEO David Ricks stated during the call:
We are seeing stronger-than-expected demand for Zepbound across all BMI cohorts, particularly in patients transitioning from semaglutide due to tolerability or efficacy preferences.
This shift is reflected in prescription trends: Symphony Health data shows that 27% of new obesity drug starts in Q1 2026 were for patients previously prescribed Wegovy, up from 19% in Q4 2025. Lilly’s forward-looking statement projects Zepbound could reach $10 billion in annual sales by 2027, potentially surpassing Wegovy if current adoption rates hold.
Market Implications: Inflation, Insurance Coverage, and Competitive Response
The obesity drug market’s expansion has macroeconomic ripple effects. A May 2025 Congressional Budget Office (CBO) analysis estimated that widespread adoption of GLP-1 agonists could reduce U.S. Obesity-related healthcare costs by $185 billion annually by 2030, but only if access expands equitably. Currently, only 42% of commercially insured patients with obesity have coverage for Wegovy or Zepbound, according to KFF, creating a two-tiered access model that limits broader economic impact.
Inflation concerns persist, as the average wholesale price (AWP) for Wegovy remains at $1,349 per month, with Zepbound at $1,059. Despite rebates, net costs to insurers average $850/month for Wegovy and $720/month for Zepbound, contributing to pharmacy trend pressures. In response, UnitedHealth Group (NYSE: UNH) and CVS Health (NYSE: CVS) have intensified prior authorization requirements, with 68% of obesity drug claims now requiring additional documentation—up from 51% in 2024.
Competitor responses are accelerating. Pfizer (NYSE: PFE) released Phase 2 data for its oral GLP-1 candidate, danuglipron, in March 2026, showing 15.2% average weight loss at 36 weeks. While not yet competitive with injectables, analysts at Bernstein note that oral options could capture 20–25% of the market by 2029 if pricing and adherence improve.
| Company | Drug | Q1 2026 Sales (USD) | YoY Growth | New Rx Share (Mar 2026) |
|---|---|---|---|---|
| Novo Nordisk (NYSE: NVO) | Wegovy | $4.1B | +12% | 52% |
| Eli Lilly (NYSE: LLY) | Zepbound | $2.8B | +89% | 38% |
| Pfizer (NYSE: PFE) | Danuglipron (Phase 2) | N/A | N/A | <1% |
The Bottom Line: Navigating a Maturing but Competitive Obesity Drug Landscape
The telehealth prescribing incident underscores systemic vulnerabilities in obesity drug delivery that could invite regulatory intervention, potentially slowing market expansion. Simultaneously, Novo Nordisk faces a dual challenge: moderating Wegovy growth due to supply constraints and rebate pressures, while losing prescription share to Eli Lilly’s faster-growing Zepbound. With obesity drug sales projected to exceed $150 billion globally by 2030, the battle for market dominance will hinge on manufacturing scale, pricing negotiations, and real-world outcomes data—factors that will determine whether these therapies deliver on their promise to reshape both public health and pharmaceutical economics.
*Disclaimer: The information provided in this article is for educational and informational purposes only and does not constitute financial advice.*
